IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.

[1]  D Hauschke,et al.  STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett’s adenocarcinomas , 2014, Oncogene.

[2]  A. Tewari,et al.  Inflammation and prostate cancer: the role of interleukin 6 (IL‐6) , 2014, BJU international.

[3]  H. Hermanns,et al.  Control of gp130 expression by the mitogen-activated protein kinase ERK2 , 2014, Oncogene.

[4]  M. Hsu,et al.  Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells , 2014, Angiogenesis.

[5]  P. Watson,et al.  Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer , 2014, Oncogene.

[6]  Hua Yu,et al.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. , 2014, Cancer research.

[7]  Yihong Yao,et al.  Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. , 2014, Pharmacology & therapeutics.

[8]  Cheng Huang,et al.  MiR-146a Regulates IL-6 Production in Lipopolysaccharide-Induced RAW264.7 Macrophage Cells by Inhibiting Notch1 , 2014, Inflammation.

[9]  Andrew R. Chin,et al.  Cytokines driving breast cancer stemness , 2014, Molecular and Cellular Endocrinology.

[10]  A. Yoshimura,et al.  Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice , 2014, Oncogene.

[11]  Mikinori Sato,et al.  Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction , 2013, British Journal of Cancer.

[12]  Ting-Ting Huang,et al.  Interplay between microRNAs and the STAT3 signaling pathway in human cancers. , 2013, Physiological genomics.

[13]  Jun Liang,et al.  Nrf2 is a potential therapeutic target in radioresistance in human cancer. , 2013, Critical reviews in oncology/hematology.

[14]  G. Garcia-Manero,et al.  Oncogenic functions of the transcription factor Nrf2. , 2013, Free radical biology & medicine.

[15]  W. Cong,et al.  Perturbation of MicroRNA‐370/Lin‐28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma , 2013, Hepatology.

[16]  M. Nieto.  Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.

[17]  X. Chen,et al.  Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.

[18]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[19]  T. Naoe,et al.  A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases , 2013, Blood Cancer Journal.

[20]  N. Ishimura,et al.  Crosstalk between TLR5 and Notch1 signaling in epithelial cells during intestinal inflammation. , 2013, International journal of molecular medicine.

[21]  Hedi Peterson,et al.  Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells , 2013, Front. Physiol..

[22]  T. Putoczki,et al.  Targeting IL-11 signaling in colon cancer , 2013, Oncotarget.

[23]  Jih-Hsiang Lee,et al.  The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo , 2013, Clinical Cancer Research.

[24]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[25]  Xiaoxia Li,et al.  IL-27, targeting antigen presenting cells, promotes Th17 differentiation and colitis in mice , 2013, Mucosal Immunology.

[26]  N. Neamati,et al.  gp130: a promising drug target for cancer therapy , 2013, Expert opinion on therapeutic targets.

[27]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[28]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[29]  Tuan-jie Li,et al.  Activation of STAT3 in Human Gastric Cancer Cells via Interleukin (IL)-6-Type Cytokine Signaling Correlates with Clinical Implications , 2013, PloS one.

[30]  A. Bosserhoff,et al.  Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. , 2013, Experimental and molecular pathology.

[31]  G. Stark,et al.  STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor , 2013, Proceedings of the National Academy of Sciences.

[32]  I. Ng,et al.  Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. , 2013, Cancer letters.

[33]  Andrew V. Nguyen,et al.  STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. , 2013, Neoplasia.

[34]  W. Wong,et al.  Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq , 2013, Nature Cell Biology.

[35]  M. Segura,et al.  microRNAs as pharmacological targets in cancer. , 2013, Pharmacological research.

[36]  V. Kuchroo,et al.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39 , 2013, Nature Immunology.

[37]  J. Scheller,et al.  Interleukin-6 and interleukin-11: same same but different , 2013, Biological chemistry.

[38]  P. Schirmacher,et al.  Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling. , 2013, Cell reports.

[39]  Mu-Kuan Chen,et al.  Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. , 2013, Experimental cell research.

[40]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[41]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[42]  S. Grivennikov.  IL-11: a prominent pro-tumorigenic member of the IL-6 family. , 2013, Cancer cell.

[43]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[44]  I. Barshack,et al.  Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. , 2013, Biochemical and biophysical research communications.

[45]  L. El-Kadre,et al.  Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver , 2013, Current opinion in clinical nutrition and metabolic care.

[46]  H. Daiko,et al.  Soluble interleukin‐6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy , 2013, Cancer science.

[47]  L. Pfeffer,et al.  Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor κB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway* , 2013, The Journal of Biological Chemistry.

[48]  A. T. Lloyd,et al.  miR-19a: An Effective Regulator of SOCS3 and Enhancer of JAK-STAT Signalling , 2013, PloS one.

[49]  O. Witte,et al.  Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues , 2013, Molecular Cancer Research.

[50]  D. Leroith,et al.  Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer , 2013, Diabetes Care.

[51]  Y. Bang,et al.  OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. , 2013, Cancer letters.

[52]  Q. Ye,et al.  MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway , 2013, Hepatology.

[53]  Shiwu Zhang,et al.  Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway , 2013, Medical Oncology.

[54]  Miao-Fen Chen,et al.  The role of IL-6 in the radiation response of prostate cancer , 2013, Radiation oncology.

[55]  Masahira Hattori,et al.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.

[56]  C. White,et al.  SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines. , 2013, JAK-STAT.

[57]  D. Ichikawa,et al.  Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. , 2013, Anticancer research.

[58]  B. Jenkins,et al.  Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. , 2013, Cytokine & growth factor reviews.

[59]  E. Elinav,et al.  Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer , 2013, Proceedings of the National Academy of Sciences.

[60]  R. Levine,et al.  Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms , 2013, International Journal of Hematology.

[61]  F. Powrie,et al.  Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model , 2013, The Journal of experimental medicine.

[62]  Miao-Fen Chen,et al.  IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer , 2013, PloS one.

[63]  J. Furuse,et al.  Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.

[64]  K. Koike,et al.  Interleukin-6 Mediates Epithelial–Stromal Interactions and Promotes Gastric Tumorigenesis , 2013, PloS one.

[65]  Miao-Fen Chen,et al.  IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus , 2013, Molecular Cancer.

[66]  G. Melillo,et al.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. , 2013, The Journal of clinical investigation.

[67]  Y. Kwon,et al.  Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. , 2013, Cellular signalling.

[68]  D. Ichikawa,et al.  Overexpression of IL-6 by gene transfer stimulates IL-8-mediated invasiveness of KYSE170 esophageal carcinoma cells. , 2013, Anticancer research.

[69]  P. Hojman,et al.  The role of intratumoral and systemic IL-6 in breast cancer , 2013, Breast Cancer Research and Treatment.

[70]  N. Neamati,et al.  Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer , 2013, Molecular Cancer Therapeutics.

[71]  C. Thiele,et al.  Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo , 2013, Oncotarget.

[72]  Zhipeng Wang,et al.  STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. , 2013, Carcinogenesis.

[73]  C. Britten.  PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types , 2013, Cancer Chemotherapy and Pharmacology.

[74]  N. Jamieson,et al.  Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[75]  M. Hallek,et al.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. , 2013, The Journal of clinical investigation.

[76]  Wei Zhang,et al.  Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. , 2013, Molecular medicine reports.

[77]  P. Guglielmelli,et al.  mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms , 2013, PloS one.

[78]  Y. Maehara,et al.  Tumor-Associated Macrophage Promotes Tumor Progression via STAT3 Signaling in Hepatocellular Carcinoma , 2013, Pathobiology.

[79]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[80]  Charles M Perou,et al.  MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 , 2013, Nature Communications.

[81]  Eugene Y. Kim,et al.  Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. , 2013, Cancer cell.

[82]  Jia Fan,et al.  Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone , 2013, Journal of Cancer Research and Clinical Oncology.

[83]  Tao Ren,et al.  IL-17 promoted metastasis of non-small-cell lung cancer cells. , 2012, Immunology letters.

[84]  H. Kulbe,et al.  The role of interleukin-6 in gynaecological malignancies. , 2012, Cytokine & growth factor reviews.

[85]  S. Yu,et al.  STAT3 & Cytochrome P450 2C9: a novel signaling pathway in liver cancer stem cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[86]  Y. Lim,et al.  Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. , 2012, Carcinogenesis.

[87]  J. Jang,et al.  Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. , 2012, Cytokine.

[88]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[89]  G. Keating,et al.  Ruxolitinib: in the treatment of myelofibrosis. , 2012, Drugs.

[90]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[91]  Z. Duan,et al.  Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.

[92]  Mukut Sharma,et al.  IL-6 activates STAT5 in T cells. , 2012, Cytokine.

[93]  M. Karin,et al.  Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. , 2012, Molecular cell.

[94]  S. Rose-John.  IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 , 2012, International journal of biological sciences.

[95]  A. Chalaris,et al.  Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease , 2012, Digestive Diseases.

[96]  D. Goldstein,et al.  STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). , 2012, International journal of oncology.

[97]  Peijing Zhang,et al.  LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker , 2012, Nature Medicine.

[98]  Z. Culig,et al.  Interleukin-6: A multifunctional targetable cytokine in human prostate cancer , 2012, Molecular and Cellular Endocrinology.

[99]  A. Stringer,et al.  Anti-Inflammatory Cytokines: Important Immunoregulatory Factors Contributing to Chemotherapy-Induced Gastrointestinal Mucositis , 2012, Chemotherapy research and practice.

[100]  Francis J. Huber,et al.  IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine , 2012, Nature.

[101]  G. Fuller,et al.  Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma , 2012, Oncotarget.

[102]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[103]  S. Sonderegger,et al.  Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3. , 2012, International journal of oncology.

[104]  Xiaomin Liu,et al.  Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer , 2012, Experimental and therapeutic medicine.

[105]  S. H. van der Burg,et al.  Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. , 2012, Current pharmaceutical design.

[106]  Y. Doki,et al.  Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma , 2012, Clinical Cancer Research.

[107]  Ho-Chul Shin,et al.  Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. , 2012, International journal of oncology.

[108]  Simion I. Chiosea,et al.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. , 2012, Cancer discovery.

[109]  Miao-Fen Chen,et al.  Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells , 2012, Journal of Molecular Medicine.

[110]  H. Hermanns,et al.  Plasticity and cross-talk of interleukin 6-type cytokines. , 2012, Cytokine & growth factor reviews.

[111]  Yaling Zhang,et al.  Inflammation-related gene expression profiles of endocervical polyps. , 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[112]  Olli Kallioniemi,et al.  Identification of MicroRNAs Inhibiting TGF-β-Induced IL-11 Production in Bone Metastatic Breast Cancer Cells , 2012, PloS one.

[113]  E. Moore,et al.  Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma. , 2012, American journal of physiology. Regulatory, integrative and comparative physiology.

[114]  C. Madeddu,et al.  Inflammation and ovarian cancer. , 2012, Cytokine.

[115]  P. Dobrzanski,et al.  The many faces of Janus kinase. , 2012, Biochemical pharmacology.

[116]  Zhao-You Tang,et al.  Expression of connective tissue growth factor and interleukin-11 in intratumoral tissue is associated with poor survival after curative resection of hepatocellular carcinoma , 2012, Molecular Biology Reports.

[117]  A. Krasinskas,et al.  The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia , 2012, Proceedings of the National Academy of Sciences.

[118]  Jongdae Lee,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.

[119]  S. Schoppmann,et al.  Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer , 2012, Clinical & Experimental Metastasis.

[120]  Weiwei Li,et al.  Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer , 2012, The International journal of biological markers.

[121]  J. Nikliński,et al.  Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. , 2012, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[122]  S. Rose-John,et al.  Therapeutic Blockade of Interleukin‐6 in Chronic Inflammatory Disease , 2012, Clinical pharmacology and therapeutics.

[123]  S. Dima,et al.  IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. , 2012, Journal of gastrointestinal and liver diseases : JGLD.

[124]  Q. Zhan,et al.  Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. , 2012, Gastroenterology.

[125]  A. Yoshimura,et al.  JAK's SOCS: a mechanism of inhibition. , 2012, Immunity.

[126]  L. Miao,et al.  Interleukin-11 Promotes the Progress of Gastric Carcinoma via Abnormally Expressed Versican , 2012, International journal of biological sciences.

[127]  Wei Guo,et al.  JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma , 2012, Clinical and Translational Oncology.

[128]  P. Dobrzanski,et al.  Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer , 2012, Molecular Cancer Therapeutics.

[129]  Robin L. Anderson,et al.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. , 2012, Genes & cancer.

[130]  K. Tsumoto,et al.  Interleukin-11 Links Oxidative Stress and Compensatory Proliferation , 2012, Science Signaling.

[131]  Toshio Tanaka,et al.  Therapeutic targeting of the interleukin-6 receptor. , 2012, Annual review of pharmacology and toxicology.

[132]  Li Lin,et al.  STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells. , 2011, Biochemical and biophysical research communications.

[133]  Zhigang Tian,et al.  Defining the critical hurdles in cancer immunotherapy , 2011, Journal of Translational Medicine.

[134]  Kevin Struhl,et al.  An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis , 2011, Cell.

[135]  Lei-na Sun,et al.  Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. , 2011, Molecular diagnosis & therapy.

[136]  O. Sansom,et al.  Absolute requirement for STAT3 function in small-intestine crypt stem cell survival , 2011, Cell Death and Differentiation.

[137]  G. Fantuzzi,et al.  Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice. , 2011, Cytokine.

[138]  E. Fu,et al.  Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. , 2011, The Journal of surgical research.

[139]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[140]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[141]  Ying Zheng,et al.  Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma , 2011, Molecular Cancer Therapeutics.

[142]  J. Datta,et al.  IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial–Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway , 2011, Molecular Cancer Research.

[143]  G. Semenza,et al.  Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 , 2011, Cell.

[144]  Y. Oike,et al.  Interleukin‐6 signalling regulates vascular endothelial growth factor‐C synthesis and lymphangiogenesis in human oral squamous cell carcinoma , 2011, The Journal of pathology.

[145]  F. Greten,et al.  Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors , 2011, Expert opinion on investigational drugs.

[146]  A. Takakura,et al.  Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. , 2011, Human molecular genetics.

[147]  O. Fardel,et al.  Regulation of drug transporter expression by oncostatin M in human hepatocytes. , 2011, Biochemical pharmacology.

[148]  Zhaoli Sun,et al.  Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. , 2011, The American journal of pathology.

[149]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[150]  T. Zimmers,et al.  STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia , 2011, PloS one.

[151]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[152]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[153]  Ying Yue,et al.  Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. , 2011, International journal of molecular medicine.

[154]  Jun Li,et al.  Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. , 2011, Experimental and therapeutic medicine.

[155]  N. Teng,et al.  Leukemia Inhibitory Factor Downregulates Human Papillomavirus-16 Oncogene Expression and Inhibits the Proliferation of Cervical Carcinoma Cells , 2011, Infectious diseases in obstetrics and gynecology.

[156]  C. McCoy,et al.  The role of miRNAs in cytokine signaling. , 2011, Frontiers in bioscience.

[157]  D. Neuberg,et al.  A dual role for the immune response in a mouse model of inflammation-associated lung cancer. , 2011, The Journal of clinical investigation.

[158]  J. Scheller,et al.  The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. , 2011, European journal of cell biology.

[159]  V. Praloran,et al.  LIF-Dependent Signaling: New Pieces in the Lego , 2011, Stem Cell Reviews and Reports.

[160]  Ashraf M Shoma,et al.  Clinical Relevance of Serum Vascular Endothelial Growth Factor and Interleukin-6 in Patients with Colorectal Cancer , 2011, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[161]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[162]  S. Akira,et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.

[163]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[164]  H. Nemoto,et al.  Methylation of OSMR gene is frequently observed in non-invasive colorectal cancer. , 2011, Anticancer research.

[165]  A. Saraya,et al.  Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma , 2011, Cellular Oncology.

[166]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[167]  G. Mouchiroud,et al.  Epidermal growth factor receptor transactivation is implicated in IL-6-induced proliferation and ERK1/2 activation in non-transformed prostate epithelial cells. , 2011, Cellular signalling.

[168]  Y. N. Park,et al.  Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans , 2011, Hepatology.

[169]  J. Shin,et al.  Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer , 2011, Molecules and cells.

[170]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[171]  Kylie L. Gorringe,et al.  IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer , 2011, Clinical Cancer Research.

[172]  M. Karin,et al.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.

[173]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[174]  Shuji Ogino,et al.  STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers , 2011, Clinical Cancer Research.

[175]  P. Gunning,et al.  Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report , 2011, Anti-cancer drugs.

[176]  S. Hsiao,et al.  IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. , 2011, Cancer research.

[177]  B. Page,et al.  Signal transducer and activator of transcription 3 inhibitors: a patent review , 2011, Expert opinion on therapeutic patents.

[178]  I. Behrmann,et al.  Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. , 2010, Biochemical pharmacology.

[179]  W. Su,et al.  Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells , 2010, Molecular Cancer.

[180]  C. Trautwein,et al.  Nrf2 Induces Interleukin-6 (IL-6) Expression via an Antioxidant Response Element within the IL-6 Promoter* , 2010, The Journal of Biological Chemistry.

[181]  T. Putoczki,et al.  More than a sidekick: the IL‐6 family cytokine IL‐11 links inflammation to cancer , 2010, Journal of leukocyte biology.

[182]  M. Neurath,et al.  VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer , 2010, The Journal of experimental medicine.

[183]  A. Krüger,et al.  Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. , 2010, Cancer genomics & proteomics.

[184]  M. Karin,et al.  Peering into the aftermath: JAKi rips STAT3 in cancer , 2010, Nature Medicine.

[185]  C. Libert,et al.  Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. , 2010, Cell metabolism.

[186]  Jian Wu,et al.  Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. , 2011, Cytokine.

[187]  P. Meikle,et al.  Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance , 2010, Diabetologia.

[188]  K. Jacobson,et al.  Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. , 2010, Gastroenterology.

[189]  Min-Chan Kim,et al.  Expression of VEGF, EGFR, and IL-6 in Gastric Adenomas and Adenocarcinomas by Endoscopic Submucosal Dissection , 2010, Digestive Diseases and Sciences.

[190]  P. Nicholls,et al.  Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma , 2010, Reproductive biology and endocrinology : RB&E.

[191]  M. Honda,et al.  Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. , 2010, Cancer research.

[192]  Ha Won Kim,et al.  MicroRNA-21 is a key determinant in IL-11/Stat3 anti-apoptotic signalling pathway in preconditioning of skeletal myoblasts. , 2010, Cardiovascular research.

[193]  T. Kishimoto.  IL-6: from its discovery to clinical applications. , 2010, International immunology.

[194]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[195]  Y. DeClerck,et al.  Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.

[196]  Jongdae Lee,et al.  ERK activation drives intestinal tumorigenesis in Apcmin/+ mice , 2010, Nature Medicine.

[197]  D. Calvisi,et al.  The Hippo–Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[198]  Judith Campisi,et al.  Senescent cells as a source of inflammatory factors for tumor progression , 2010, Cancer and Metastasis Reviews.

[199]  T. Smyrk,et al.  Upregulation of DNA Methyltransferase–Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6 , 2010, Molecular Cancer Research.

[200]  L. Marchand,et al.  Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population , 2010, Cancer Causes & Control.

[201]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[202]  M. Karin,et al.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. , 2010, Cancer cell.

[203]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[204]  D. Zelterman,et al.  Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[205]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[206]  Andrew V. Nguyen,et al.  A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. , 2010, The American journal of pathology.

[207]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[208]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[209]  M. Karin,et al.  Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. , 2010, Cancer cell.

[210]  M. Sata,et al.  Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model , 2009, The Journal of Immunology.

[211]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[212]  M. Karin,et al.  Ikappa B kinaseβ/nuclear factor‐κB activation controls the development of liver metastasis by way of interleukin‐6 expression , 2009, Hepatology.

[213]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[214]  N. Kato,et al.  Serum IL‐6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences , 2009, International journal of cancer.

[215]  J. Kanda,et al.  Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines , 2009, International journal of hematology.

[216]  Kevin Struhl,et al.  An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation , 2009, Cell.

[217]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[218]  A. Giraud,et al.  Cytokine signalling via gp130 in gastric cancer. , 2009, Biochimica et biophysica acta.

[219]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[220]  Guotai Xu,et al.  Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. , 2009, Molecular medicine reports.

[221]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[222]  G. Meijer,et al.  Promoter DNA Methylation of Oncostatin M receptor-β as a Novel Diagnostic and Therapeutic Marker in Colon Cancer , 2009, PloS one.

[223]  Herbert Schulz,et al.  Novel STAT3 Target Genes Exert Distinct Roles in the Inhibition of Mesoderm and Endoderm Differentiation in Cooperation with Nanog , 2009, Stem cells.

[224]  D. Hori,et al.  Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma , 2009, British Journal of Cancer.

[225]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[226]  S. Tatebe,et al.  Serum interleukin-6 and -10 levels in patients with gastric cancer , 2009, Gastric Cancer.

[227]  J. Scheller,et al.  Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. , 2009, Current pharmaceutical design.

[228]  Rong Li,et al.  Interleukin 6 Secreted from Adipose Stromal Cells Promotes Migration and Invasion of Breast Cancer Cells , 2009, Oncogene.

[229]  Cristina M. Tato,et al.  IL-27 Blocks RORc Expression to Inhibit Lineage Commitment of Th17 Cells , 2009, The Journal of Immunology.

[230]  E. Tian,et al.  c-Met signaling promotes IL-6-induced myeloma cell proliferation , 2009, European journal of haematology.

[231]  A. Giraud,et al.  STAT3 as a prognostic marker in human gastric cancer , 2009, Journal of gastroenterology and hepatology.

[232]  Hiroko Oshima,et al.  The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. , 2009, Gastroenterology.

[233]  A. Kulig,et al.  Clinical Significance of Interleukin-6 (Il-6) Gene Polymorphism and Il-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis , 2009, Digestive Diseases and Sciences.

[234]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[235]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[236]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[237]  Y. Hannun,et al.  Role for sphingosine kinase 1 in colon carcinogenesis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[238]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[239]  H. Yoshida,et al.  Regulation of immune responses by interleukin‐27 , 2008, Immunological reviews.

[240]  Wei Zhang,et al.  beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. , 2008, Cancer letters.

[241]  F. Ali-Osman,et al.  Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators , 2008, Clinical Cancer Research.

[242]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[243]  P. Halban,et al.  Interleukin-6 regulates pancreatic α-cell mass expansion , 2008, Proceedings of the National Academy of Sciences.

[244]  Gary Hardiman,et al.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. , 2008, Cancer cell.

[245]  R. Homer,et al.  Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. , 2008, American journal of respiratory cell and molecular biology.

[246]  J. Karras,et al.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. , 2008, Journal of Clinical Investigation.

[247]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[248]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[249]  C. Pecquet,et al.  Mining for JAK-STAT mutations in cancer. , 2008, Trends in biochemical sciences.

[250]  C. Porta,et al.  Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[251]  R. Beyer,et al.  Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. , 2008, The Journal of experimental medicine.

[252]  Wei-Chih Liao,et al.  Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma , 2008, Clinical Cancer Research.

[253]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[254]  M. Ricote,et al.  OSM, LIF, Its Receptors, and Its Relationship with the Malignance in Human Breast Carcinoma (In Situ and in Infiltrative) , 2008, Cancer investigation.

[255]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[256]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[257]  Kathleen R. Cho,et al.  Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. , 2007, Cancer research.

[258]  Ana Quaglino,et al.  Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling , 2007, Breast Cancer Research.

[259]  J. Grandis,et al.  STAT‐mediated EGFR signaling in cancer , 2007, Journal of cellular biochemistry.

[260]  A. Boussioutas,et al.  Augmented gp130‐mediated cytokine signalling accompanies human gastric cancer progression , 2007, The Journal of pathology.

[261]  Y. S. Kim,et al.  Diagnostic Utility of Interleukin-6 (IL-6) for Primary Bile Duct Cancer and Changes in Serum IL-6 Levels Following Photodynamic Therapy , 2007, The American Journal of Gastroenterology.

[262]  Jörg Hackermüller,et al.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.

[263]  W. Alexander,et al.  Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. , 2007 .

[264]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[265]  T. Yeatman,et al.  Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer , 2007, Genome Biology.

[266]  N. Coleman,et al.  Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome , 2007, The Journal of pathology.

[267]  J. Bartlett,et al.  Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer , 2007, British Journal of Cancer.

[268]  Y. Jeng,et al.  IL‐6 induces AGS gastric cancer cell invasion via activation of the c‐Src/RhoA/ROCK signaling pathway , 2007, International journal of cancer.

[269]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[270]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[271]  Genee Y. Lee,et al.  Targeting the tumor microenvironment. , 2007, Frontiers in bioscience : a journal and virtual library.

[272]  K. Shichijo,et al.  Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. , 2007, International journal of oncology.

[273]  M. Ogawa,et al.  Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. , 2007, International journal of oncology.

[274]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[275]  T. Patel,et al.  The MicroRNA let-7a Modulates Interleukin-6-dependent STAT-3 Survival Signaling in Malignant Human Cholangiocytes* , 2007, Journal of Biological Chemistry.

[276]  R. Jove,et al.  Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. , 2007, Urology.

[277]  J. Lin,et al.  Stat3 activation in human endometrial and cervical cancers , 2007, British Journal of Cancer.

[278]  W. Alexander,et al.  Opposing roles of gp130‐mediated STAT‐3 and ERK‐1/2 signaling in liver progenitor cell migration and proliferation , 2007, Hepatology.

[279]  T. Nakayama,et al.  Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. , 2007, International journal of oncology.

[280]  M. Cairo,et al.  The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes , 2007, Leukemia & lymphoma.

[281]  R. Bast,et al.  The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis , 2006, Cancer.

[282]  J. Heath,et al.  Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. , 2006, Cancer research.

[283]  T. Nakayama,et al.  Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells. , 2006, International journal of oncology.

[284]  B. Mellado,et al.  Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity , 2006, Clinical Cancer Research.

[285]  L. Hennighausen,et al.  Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system , 2006, Nature Immunology.

[286]  W. Kung,et al.  Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways , 2006, Oncogene.

[287]  C. Chai,et al.  Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma , 2006, Journal of Clinical Pathology.

[288]  Helen H. W. Chen,et al.  Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion , 2006, Oncogene.

[289]  Y. Maehara,et al.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.

[290]  J. Fenton,et al.  Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. , 2006, Carcinogenesis.

[291]  D. Berry,et al.  Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 , 2006, Breast Cancer Research and Treatment.

[292]  Toshiyuki Nakayama,et al.  Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. , 2006, Oncology reports.

[293]  S. Akira,et al.  Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. , 2006, Genes & development.

[294]  M. Pirisi,et al.  Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival , 2006, Cancer Immunology, Immunotherapy.

[295]  M. Soresi,et al.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[296]  T. Patel,et al.  Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. , 2006, Life sciences.

[297]  J. Schulzke,et al.  Randomized, Double Blind Controlled Trial of Subcutaneous Recombinant Human Interleukin-11 Versus Prednisolone in Active Crohn's Disease , 2006, The American Journal of Gastroenterology.

[298]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[299]  T. Nagayasu,et al.  Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors. , 2006, World journal of gastroenterology.

[300]  Chi-Ying F. Huang,et al.  IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[301]  N. L. La Gruta,et al.  Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. , 2005, Gastroenterology.

[302]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[303]  T. Nheu,et al.  Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling , 2005, Nature Medicine.

[304]  Jung Weon Lee,et al.  The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .

[305]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[306]  M. Ricote,et al.  IL‐6, its receptors and its relationship with bcl‐2 and bax proteins in infiltrating and in situ human breast carcinoma , 2005, Histopathology.

[307]  S. Bellone,et al.  High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. , 2005, Gynecologic oncology.

[308]  B. Gao,et al.  Cytokines, STATs and liver disease. , 2005, Cellular & molecular immunology.

[309]  A. Miyajima,et al.  Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes. , 2005, The American journal of pathology.

[310]  K. Aldape,et al.  Expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Expression of Vascular Endothelial Growth Factor in and Angiogenic Phenotype of Human Gastric Cancer , 2005, Clinical Cancer Research.

[311]  M. Neurath,et al.  IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer , 2005, Cell cycle.

[312]  Volker Briese,et al.  Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[313]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[314]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[315]  J. Blay,et al.  IL‐6 as an intracrine growth factor for renal carcinoma cell lines , 2004, International journal of cancer.

[316]  T. Hirano,et al.  IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation1 , 2004, The Journal of Immunology.

[317]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[318]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[319]  P. Kern,et al.  Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. , 2004, American journal of physiology. Endocrinology and metabolism.

[320]  Hsiu‐Po Wang,et al.  Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. , 2004, Journal of biomedical science.

[321]  N. Songür,et al.  Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Tumori.

[322]  P. Troncoso,et al.  Combinatorial Screenings in Patients , 2004, Cancer Research.

[323]  Shiu-Feng Huang,et al.  Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways , 2003, Oncogene.

[324]  B. Wiedenmann,et al.  Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. , 2003, Gastroenterology.

[325]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[326]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[327]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[328]  E. van Marck,et al.  Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.

[329]  P. Real,et al.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells , 2002, Oncogene.

[330]  C. Marth,et al.  Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[331]  B. Jenkins,et al.  Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice , 2002, Nature Medicine.

[332]  M. Oya,et al.  Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. , 2002, The Journal of urology.

[333]  M. Soresi,et al.  Circulating IL‐6 and sIL‐6R in Patients with Hepatocellular Carcinoma , 2002, Annals of the New York Academy of Sciences.

[334]  T. Nakatani,et al.  Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma , 2002, British Journal of Cancer.

[335]  P. Quesenberry,et al.  Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. , 2002, Cytokine.

[336]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[337]  D. Hilton,et al.  Negative regulation of cytokine signaling , 2001, Journal of leukocyte biology.

[338]  H. Fuse,et al.  Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. , 2001, Biochemical and biophysical research communications.

[339]  E. Keller,et al.  Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.

[340]  P. Quesenberry,et al.  Interleukin-11 receptor expression in primary ovarian carcinomas. , 2001, Gynecologic oncology.

[341]  C. Begley,et al.  Oncostatin M and Leukemia Inhibitory Factor Regulate the Growth of Normal Human Breast Epithelial Cells , 2001, Growth factors.

[342]  Jiayuh Lin,et al.  Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. , 2000, Gynecologic oncology.

[343]  C. Ogle,et al.  Interleukin-6 signal transduction in human intestinal epithelial cells. , 2000, Shock.

[344]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[345]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[346]  J. Jessup,et al.  Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer , 2000, Annals of Surgical Oncology.

[347]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[348]  K. Chow,et al.  Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate , 1999, British Journal of Cancer.

[349]  Guo‐Jun Zhang,et al.  Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. , 1999, Anticancer research.

[350]  L. Chauvelot‐Moachon,et al.  Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. , 1999, European cytokine network.

[351]  C. Tohyama,et al.  Tumor growth and food intake in interleukin-6 gene knock-out mice. , 1998, Cancer letters.

[352]  P. Musiani,et al.  Coexpression of IL‐6 and soluble IL‐6R causes nodular regenerative hyperplasia and adenomas of the liver , 1998, The EMBO journal.

[353]  J. Punnonen,et al.  Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors , 1998, Cancer.

[354]  Keigo Nishida,et al.  Gab1 Acts as an Adapter Molecule Linking the Cytokine Receptor gp130 to ERK Mitogen-Activated Protein Kinase , 1998, Molecular and Cellular Biology.

[355]  J. Castell,et al.  Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[356]  Weiliang Tang,et al.  Transforming Growth Factor-β Stimulates Interleukin-11 Transcription via Complex Activating Protein-1-dependent Pathways* , 1998, The Journal of Biological Chemistry.

[357]  G. Hortobagyi,et al.  Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism , 1998, Breast Cancer Research and Treatment.

[358]  James S Goydos,et al.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. , 1998, Annals of surgery.

[359]  A. Bardelli,et al.  Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.

[360]  C. Begley,et al.  Oncostatin M induces the differentiation of breast cancer cells , 1998, International journal of cancer.

[361]  H. Hollema,et al.  Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. , 1997, European journal of cancer.

[362]  K. Grankvist,et al.  Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. , 1997, European journal of cancer.

[363]  M. Picot,et al.  Expression of the interleukin 6 receptor in primary renal cell carcinoma. , 1997, Journal of clinical pathology.

[364]  C. Begley,et al.  Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. , 1997, Blood.

[365]  R. Oyasu,et al.  Interleukin‐6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro , 1997, International journal of cancer.

[366]  E. Tartour,et al.  IL-6 is a survival prognostic factor in renal cell carcinoma. , 1997, Immunology letters.

[367]  C. O’Brien,et al.  Isolation and Characterization of the Human gp130 Promoter , 1997, The Journal of Biological Chemistry.

[368]  M. Spence,et al.  Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[369]  M. Spence,et al.  Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells. , 1997, Cancer research.

[370]  P. Musiani,et al.  Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. , 1997, British Journal of Cancer.

[371]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[372]  H. Kosmehl,et al.  Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[373]  S. Thorgeirsson,et al.  Expression of leukemia inhibitory factor and its receptor during liver regeneration in the adult rat. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[374]  N. Iizuka,et al.  Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. , 1996, Cancer research.

[375]  A. Belldegrun,et al.  Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. , 1995, Cancer research.

[376]  J. Gauldie,et al.  Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). , 1995, Cytokine.

[377]  O. Yoshida,et al.  Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. , 1995, Cancer research.

[378]  E. Tartour,et al.  Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. , 1994, Cancer research.

[379]  E. Heyderman,et al.  Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. , 1993, Gynecologic oncology.

[380]  K. Nishio,et al.  Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. , 1993, British Journal of Cancer.

[381]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[382]  T. Hirano,et al.  Enhanced expression of interleukin-6 in primary human renal cell carcinomas. , 1991, Journal of the National Cancer Institute.

[383]  J. Berek,et al.  Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. , 1990, Cancer research.

[384]  Masahiro Yamamoto,et al.  Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas , 1989, FEBS letters.

[385]  J. Coward,et al.  Interleukin-6: an angiogenic target in solid tumours. , 2014, Critical reviews in oncology/hematology.

[386]  K. Chayama,et al.  Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study , 2014, International journal of cancer.

[387]  K. Kiura,et al.  Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. , 2014, Lung cancer.

[388]  Sagar Ghosh,et al.  An IL-6 link between obesity and cancer. , 2013, Frontiers in bioscience.

[389]  B. Aggarwal,et al.  Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials , 2012, The AAPS Journal.

[390]  Xiao-li Li,et al.  Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[391]  X. Sun,et al.  The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. , 2012, Neoplasma.

[392]  J. Marrero,et al.  Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. , 2012, Cancer biomarkers : section A of Disease markers.

[393]  G. Yang,et al.  The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. , 2011, Neoplasma.

[394]  Caijie Li,et al.  Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer , 2011, Pathology & Oncology Research.

[395]  Amy R. Peck,et al.  Signal transducer and activator of transcription-3 and breast cancer prognosis. , 2011, American journal of cancer research.

[396]  T. Putoczki,et al.  ReviewStat 3 : linking inflammation to epithelial cancer-more than a " gut " feeling ? , 2015 .

[397]  H. Jabbour,et al.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. , 2010, The American journal of pathology.

[398]  H. Friess,et al.  Liver macrophages contribute to pancreatic cancer-related cachexia. , 2009, Oncology reports.

[399]  Christopher F. Martin,et al.  Circulating levels of inflammatory cytokines and risk of colorectal adenomas. , 2008, Cancer research.

[400]  S. Forbes,et al.  Activation of stem cells in hepatic diseases , 2007, Cell and Tissue Research.

[401]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[402]  V. Chopra,et al.  Serum levels of interleukins, growth factors and anglogenin in patients with endometrial cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[403]  F. Zunino,et al.  Overview of tumor cell chemoresistance mechanisms. , 2005, Methods in molecular medicine.

[404]  Tetsuo Sumi,et al.  Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor , 2005, Gastric Cancer.

[405]  G. Ishii,et al.  Interleukin-6 (IL-6) production in carcinoma of the cervix , 2005, Archives of Gynecology and Obstetrics.

[406]  H. Fuse,et al.  Serum Interleukin-11 in Patients with Benign Prostatic Hyperplasia and Prostate Cancer , 2004, International Urology and Nephrology.

[407]  C. Ohlsson,et al.  Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.

[408]  T. Savarese,et al.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.

[409]  E. Keller,et al.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.

[410]  T. Chung,et al.  Interleukin‐6 activates phosphatidylinositol‐3 kinase, which inhibits apoptosis in human prostate cancer cell lines , 2000 .

[411]  T. Okusaka,et al.  Elevated serum interleukin-6 levels in patients with pancreatic cancer. , 1998, Japanese journal of clinical oncology.

[412]  E. Hannigan,et al.  Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. , 1998, Cancer investigation.

[413]  Z. Estrov,et al.  Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[414]  M. Ogawa,et al.  Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). , 1994, Research communications in molecular pathology and pharmacology.

[415]  J. Gauldie,et al.  Regulation of IL-6 and the hepatic IL-6 receptor in acute inflammation in vivo. , 1993, Cytokine.

[416]  C. Jorcyk,et al.  Cancer Management and Research Dovepress Clinical Significance of Interleukin (il)-6 in Cancer Metastasis to Bone: Potential of Anti-il-6 Therapies , 2022 .

[417]  C. Creighton,et al.  Cancer Management and Research Dovepress the Role of Epithelial–mesenchymal Transition Programming in Invasion and Metastasis: a Clinical Perspective , 2022 .